Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492901 | 0.93 | MAPK1 (0.67) | CHRNA7MAPK1MAPTRAB9ANPC1 | |
| SCHEMBL4918783 | 0.90 | MAPK1 (0.60) | CHRNA7MAPK1MAPTRAB9ANPC1 | |
| SCHEMBL5922316 | 0.88 | CHRNA7 (0.58) | CHRNA7MAPK1MAPTRAB9ALMNA | |
| SCHEMBL4924236 | 0.87 | MAPK1 (0.57) | CHRNA7MAPK1MAPTRAB9ANPC1 | |
| SCHEMBL5922313 | 0.86 | CHRNA7 (0.56) | CHRNA7MAPK1MAPTALDH1A1HPGD | |
| SCHEMBL2888752 | 0.85 | CHRNA7 (0.72) | CHRNA7MAPK1MAPTTP53LMNA | |
| SCHEMBL5922342 | 0.82 | CHRNA7 (0.72) | CHRNA7MAPK1MAPTTP53LMNA | |
| SCHEMBL7172634 | 0.81 | LMNA (0.67) | CHRNA7MAPK1MAPTTP53LMNA | |
| SCHEMBL14270596 | 0.81 | CNR1 (0.53) | CHRNA7MAPK1MAPTNPC1SMN1; SMN2 | |
| SCHEMBL5922348 | 0.80 | LMNA (0.69) | CHRNA7MAPTTP53LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122230-A1 | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| US-20060122230-A1 | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1592404-A1 | AQUEOUS DISPERSION COMPRISING STABLE NANOPARTICLES OF A WATER-INSOLUBLE PYRROLE CARBOXAMIDE AND AN EXCIPIENT LIKE MIDDLE CHAIN TRIGLYCERIDES | AstraZeneca AB (SE) | 2005-11-09 | — | — | EP | disclosed |
| EP-1578417-A1 | 1,5-DIARYL-PYRROLE-3-CARBOXAMIDE DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004069227-A1 | AQUEOUS DISPERSION COMPRISING STABLE NANOPARTICLES OF A WATER-INSOLUBLE PYRROLE CARBOXAMIDE AND EXCIPIENT LIKE MIDDLE CHAIN TRIGLYCERIDES | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004058249-A1 | 1,5-DIARYL-PYRROLE-3-CARBOXAMIDE DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122230-A1 | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | CHRNA7 146/4885MAPK1 2156/4885MAPT 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.